Atorvastatin-associated neurological adverse events: a disproportionality analysis with adjustment for confounding by indication - Top-Institutions - MDSpire

Atorvastatin-associated neurological adverse events: a disproportionality analysis with adjustment for confounding by indication

  • By

  • Xinjun He

  • Qi Zhou

  • Min Zhang

  • Dandan Wang

  • Xinchang Xu

  • July 7, 2026

  • 0 min

Share

Top Institutions in Neurology

Brief introduction explaining scope and methodology.

  • #1

    Massachusetts General Hospital
    Massachusetts General Hospital

    Boston, MA

    Key Differentiators

    • Neurology

  • #2

    Khon Kaen University Hospital
    Khon Kaen University Hospital

    Khon Kaen, Thailand

    Key Differentiators

    • Neurology

  • #3

    Chinese tertiary medical centers
    Chinese tertiary medical centers

    Various, China

    Key Differentiators

    • Neurology

  • #4

    PROspective Study of Pravastatin in Elderly at Risk (PROSPER)
    PROspective Study of Pravastatin in Elderly at Risk (PROSPER)

    Various, Various

    Key Differentiators

    • Neurology

  • #5

    Secondary Manifestations of ARTerial disease (SMART)
    Secondary Manifestations of ARTerial disease (SMART)

    Various, Various

    Key Differentiators

    • Neurology

Original Source(s)

Atorvastatin-associated neurological adverse events: a disproportionality analysis with adjustment for confounding by indication

  • by Xinjun He, Qi Zhou, Min Zhang, Dandan Wang, Xinchang Xu

  • July 7, 2026

Related Content

Transcranial focused ultrasound stimulation in schizophrenia: current evidence, mechanisms, and future directions

Risk factors and intervention strategies for lower extremity deep vein thrombosis after intravenous thrombolysis for acute ischemic stroke

Head-to-Head Trial in Relapsing MS

The phase 3 OVERLORD-MS trial compared 2 anti-CD20 therapies in previously untreated adults with newly diagnosed relapsing multiple sclerosis and recent inflammatory disease activity.